Hisamitsu Pharmaceutical CoFSE:4530 89 EBITDA Margin % is 7.18% as of Nov. 2025, which is 64% below its 10-year median of 20.22. GuruFocus rates FSE:4530 with a GF Score™ of 89/100 and a GF Value™ of 円3,237.07. Among 955 Drug Manufacturers companies, Hisamitsu Pharmaceutical Co ranks better than 65.55% on this metric.
Hisamitsu Pharmaceutical Co (FSE:4530) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Hisamitsu Pharmaceutical Co EBITDA Margin % Related Terms
Hisamitsu Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hisamitsu Pharmaceutical Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Hisamitsu Pharmaceutical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hisamitsu Pharmaceutical Co (FSE:4530) has a EBITDA Margin % of 7.18% as of Nov. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hisamitsu Pharmaceutical Co and its competitors. This is 64% below median its historical median of 20.22. Over the past decade, Hisamitsu Pharmaceutical Co's EBITDA Margin % has ranged from 14.22 to 25.62. According to the industry distribution chart, Hisamitsu Pharmaceutical Co ranks #329 out of 955 companies in the Drug Manufacturers industry, placing it in the top 34.5%.
Is Hisamitsu Pharmaceutical Co's EBITDA Margin % too high?
Hisamitsu Pharmaceutical Co's current EBITDA Margin % of 7.18% is 64% below median its 10-year median of 20.22. Over the past 10 years, this metric has ranged from a low of 14.22 to a high of 25.62. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Hisamitsu Pharmaceutical Co's value of 7.18% is 42.1% below this industry median. Based on the distribution chart, Hisamitsu Pharmaceutical Co ranks #329 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Hisamitsu Pharmaceutical Co ranks #329 out of 955 companies for EBITDA Margin %. This puts Hisamitsu Pharmaceutical Co in the upper half of its industry. The industry median EBITDA Margin % is 12.39. Hisamitsu Pharmaceutical Co's value of 7.18% is 42.1% below this benchmark. Historically, Hisamitsu Pharmaceutical Co's own EBITDA Margin % has ranged from 14.22 to 25.62 over the past decade. While the company's 10-year median is 20.22 vs. the industry median of 12.39, Hisamitsu Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hisamitsu Pharmaceutical Co's current EBITDA Margin % of 7.18% is 42.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hisamitsu Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hisamitsu Pharmaceutical Co's current EBITDA Margin % is 7.18%, which is 64% below median its own 10-year median of 20.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FSE:4530) has a current EBITDA Margin % of 7.18%. The stock's GF Value™ is 円3,237.07, compared to a current price of 円3,975.00 — trading 22.8% above its estimated fair value. The current EBITDA Margin % is 7.18%, which is 64% below median its 10-year median of 20.22 and 42.1% below the Drug Manufacturers industry median of 12.39. Hisamitsu Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FSE:4530), the current EBITDA Margin % is 7.18% as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.
Key valuation signals for FSE:4530:
EBITDA Margin %: 7.18% (64% below median its 10-year median of 20.22)
GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
Industry Position: 42.1% below the Drug Manufacturers median (#329 of 955)
No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
89GF Score
Get the complete analysis for FSE:4530
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSE:4530 has been successfully added to your 
